According to a post on the FDA’s website, Regeneron’s treatment of Hemophilia B was granted orphan designation.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
- Regeneron to host conference call
- Regeneron price target raised by $27 at Morgan Stanley, here’s why
- Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year
- Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes